CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma

Regorafenib is used for hepatocellular carcinoma (HCC), but its response does not last long, partly due to chemoresistance acquisition. We performed a clustered regularly interspaced short palindromic repeats (CRISPR)-based loss-of-function genetic screen and aimed to discover molecules involved in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Suemura, Shigeki, Kodama, Takahiro, Myojin, Yuta, Yamada, Ryoko, Shigekawa, Minoru, Hikita, Hayato, Sakamori, Ryotaro, Tatsumi, Tomohide, Takehara, Tetsuo
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770429/
https://ncbi.nlm.nih.gov/pubmed/31540262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091362
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki